{"index": {"_index": "jga-study","_id": "JGAS000675"}}
{"properties": {"alias": "JSUB000945_Study_000001","center_name": "Individual","accession": "JGAS000675","DESCRIPTOR": {"STUDY_TITLE": "RNA sequencing of surgically removed lung adenocarcinoma afterwards treated with immune checkpoint inhibitors","STUDY_TYPES": {"STUDY_TYPE": {"existing_study_type": "Transcriptome Sequencing"}},"STUDY_ABSTRACT": "Patients with lung adenocarcinoma (LUAD) from The Cancer Genome Atlas (TCGA) database were enrolled in the training cohort to establish a prognostic signature based on the expression of tumor-specific amino acid metabolism related genes. The established signature was further investigated against an original cohort, KCC-ICI, of chemotherapy combined with immune checkpoint inhibitors. The signature consisting of nine genes, KYNU, PSPH, PPAT, MIF, GCLC, ACAD8, TYRP1, ALDH2, and HDC, could effectively stratify the OS in LUAD patients. The KCC-ICI cohort confirmed the predictive ability of the established signature in the clinical response to immune checkpoint blockade therapy, which correlated with the infiltration of immune cells (e.g., T lymphocytes and nature killer cells). We discovered that the high signature risk score patients showed a significantly lower concentration of plasma-free ??-aminobutyric acid (AABA)."},"GRANTS": {"GRANT": {"grant_id": "19213835","TITLE": "Exploratory study for stratification marker of immune checkpoint inhibitor in patients with advanced or recurrent non-small cell lung cancer","AGENCY": {"abbr": "AMED","content": "Japanese Agency for Medical Research and Development"}}},"STUDY_ATTRIBUTES": {"STUDY_ATTRIBUTE": [{"TAG": "NBDC Number","VALUE": "hum0442"},{"TAG": "Registration date","VALUE": "2024-02-29"},{"TAG": "Submitting organization","VALUE": "Kanagawa Cancer Center Research Institute"},{"TAG": "Principal Investigator","VALUE": "Tetsuro Sasada"},{"TAG": "Molecular Data Type","VALUE": "RNA sequeicing"},{"TAG": "Platform","VALUE": "NovaSeq 6000"},{"TAG": "Vendor","VALUE": "Illumina"},{"TAG": "Comment","VALUE": "Analysis by TAKARA bio Inc."},{"TAG": "Primary Phenotype","VALUE": "Lung adenocarcinoma (HP:0030078)"},{"TAG": "ICD-10 Disease Classification","VALUE": "adenocarcinoma (C349)"},{"TAG": "adenocarcinoma","VALUE": "RNA sequencing"}]}},"identifier": "JGAS000675","title": "RNA sequencing of surgically removed lung adenocarcinoma afterwards treated with immune checkpoint inhibitors","description": "Patients with lung adenocarcinoma (LUAD) from The Cancer Genome Atlas (TCGA) database were enrolled in the training cohort to establish a prognostic signature based on the expression of tumor-specific amino acid metabolism related genes. The established signature was further investigated against an original cohort, KCC-ICI, of chemotherapy combined with immune checkpoint inhibitors. The signature consisting of nine genes, KYNU, PSPH, PPAT, MIF, GCLC, ACAD8, TYRP1, ALDH2, and HDC, could effectively stratify the OS in LUAD patients. The KCC-ICI cohort confirmed the predictive ability of the established signature in the clinical response to immune checkpoint blockade therapy, which correlated with the infiltration of immune cells (e.g., T lymphocytes and nature killer cells). We discovered that the high signature risk score patients showed a significantly lower concentration of plasma-free ??-aminobutyric acid (AABA).","name": "JSUB000945_Study_000001","type": "jga-study","url": "https://ddbj.nig.ac.jp/resource/jga-study/JGAS000675","sameAs": null,"isPartOf": "jga","organism": {"identifier": 9606,"name": "Homo sapiens"},"dbXrefs": [{"identifier": "JGAP000001","type": "jga-policy","url": "https://ddbj.nig.ac.jp/resource/jga-policy/JGAP000001"},{"identifier": "JGAC000001","type": "jga-dac","url": "https://ddbj.nig.ac.jp/resource/jga-dac/JGAC000001"},{"identifier": "JGAD000805","type": "jga-dataset","url": "https://ddbj.nig.ac.jp/resource/jga-dataset/JGAD000805"}],"status": "public","visibility": "unrestricted-access","dateCreated": "2024-02-29T12:30:52+09:00","dateModified": "2024-03-01T12:30:51+09:00","datePublished": "2024-08-09T15:50:42+09:00"}